查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1828004

心臟衰竭藥物市場（按藥物類別、心臟衰竭類型、給藥方法、最終用戶和分銷管道分類）—2025-2032 年全球預測

Heart Failure Therapeutics Market by Drug Class, Heart Failure Type, Mode Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年心臟衰竭藥物市場規模將成長至 602.3 億美元，複合年成長率為 10.98%。

主要市場統計數據
基準年2024年 261.6億美元
預計2025年 291億美元
預測年份：2032年 602.3億美元
複合年成長率（%） 10.98%

現代心臟衰竭藥物的簡潔、情境化框架強調了臨床重點、護理途徑和相關人員的決策工具

心臟衰竭藥物處於臨床緊迫性、不斷發展的分子科學和不斷變化的醫療服務模式的關鍵交叉點。本執行摘要總結了臨床醫生、付款人、行業領導者和政策制定者的當前形勢，重點介紹了對患者預後最關鍵的治療層級和護理途徑。引言部分將最新的治療方法進展置於不斷變化的臨床指南和對慢性病管理日益關注的背景下，其餘分析則組裝於實際意義而非抽象的預測。

本文重點介紹了現有藥物類別的漸進式創新，以及新藥物和輔助治療策略如何重新定義治療流程。此外，本文也強調了影響日常實踐中採用這些藥物的實際因素，例如給藥途徑、急性和慢性治療的差異，以及診所、醫院和家庭環境。透過將研究內容與現實世界的決策促進因素連結起來，本節將引導讀者更深入分析未來前景、關稅影響、市場區隔洞察以及區域動態。

本書始終在臨床細節和商業性實用性之間保持平衡。引言並非試圖逐一列舉每一項進展，而是重點闡述了決定治療價值、相關人員優先考慮的問題，以及各機構應如何調整運作以抓住心臟衰竭治療領域的新機會。

深入分析藥理學創新、複雜的表現型分析和不斷發展的醫療服務模式如何共同重塑治療策略和獲取途徑

技術創新、指南演變和醫療服務重新設計等因素共同作用，正在改變心臟衰竭治療格局。藥理學的進步正在擴展臨床醫生的套件，使其不再局限於傳統的血流動力學藥物，而是涵蓋針對代謝、發炎和腎心軸的藥物。因此，ACE抑制劑、ARB、 BETA阻斷劑、利尿劑、MRAs和SGLT2抑制劑等既定類別正在更精細的治療方案中重新評估，並相應地強調聯合策略和給藥順序。

同時，診斷的改進和對錶型異質性的更深入理解，集中在區分射血分數保留型和降低型亞型以及急性和慢性疾病。這些臨床定義影響治療方法選擇、監測強度和預期結果。給藥偏好也在發生變化，與住院模式和擴大居家照護相關的口服慢性方案與間歇性或急性靜脈注射之間的相互作用也在發生變化。

從營運角度來看，分銷和獲取管道正在同步轉型。雖然線下通路（主要是醫院和零售藥局）對於急診和專科配藥仍然至關重要，但線上履約和遠端醫療醫療處方在慢性病用藥的連續性方面正日益受到青睞。終端使用者診所、居家醫療機構和醫院正在適應新的用藥啟動、劑量調整和監測方案，重塑了實證醫學轉化為實踐的方式。這些累積效應導致治療方法選擇、護理環境和獲取機制的格局迅速演變，需要在臨床、商業和政策領域制定協調一致的策略。

對近期關稅主導的供應鏈效應及其對採購、分銷和治療准入框架的營運影響全面評估。

美國近期的關稅變化對心臟衰竭治療領域的製造商、經銷商和下游醫療保健提供者產生了多重影響。關稅變化將影響整個供應鏈的成本結構，影響原料藥藥物成分、成品製劑以及用於監測和給藥的設備相關產品的到岸成本。這些壓力可能會改變與醫院系統和藥房網路的合約動態，並可能促使公共和私人付款人重新評估籌資策略。

營運連鎖反應延伸至通路經濟。醫院藥房採購慣例、零售藥房備貨決策以及線上分銷協議都對關稅調整引起的投入成本波動敏感。為此，製造商可能會在地採購、與其他供應商合作或重新協商分銷條款，以保護利潤率並確保患者獲得藥品的連續性。同樣，採用基於價值的支付安排的醫療保健提供者可能會重新評估處方和護理途徑，以在維持臨床標準的同時管理總護理成本。

臨床醫生和衛生系統領導者需要在短期營運調整與長期韌性措施之間取得平衡。這需要供應鏈、藥房和臨床領導層之間更緊密的合作；加強對潛在供應中斷的情境規劃；並與付款人進行策略對話，以確保患者能夠獲得指南推薦的療法。最終，關稅帶來的成本壓力將成為整個醫療服務生態系統中更一體化的採購和治療管理實踐的催化劑。

透過多維細分洞察來引導您的目標策略，協調藥物類別、表現型差異、給藥途徑、治療環境和分銷架構

細分提供了將治療差異轉化為可操作策略所需的分析框架。從藥物類別來看，治療方法選擇差異顯著：ACE 抑制劑和 ARB 仍然是神經激素調節的基石， BETA阻斷劑可緩解交感神經興奮過度，利尿劑可管理有症狀患者的體液平衡，MRA 有助於拮抗劑可緩解交感神經興奮過度，利尿劑可管理有症狀患者的體液平衡，MRA 有助於拮抗劑抗鹽皮質激素，而 SGLT2 抑製劑則超越了傳統的藥物類別界限，提供代謝和腎臟/心臟益處。這些類別層面的差異直接影響臨床路徑和商業性定位。

依心臟衰竭類型分類可進一步完善決策。射血分數保留和降低在生物學和操作上是截然不同的領域，與慢性維持治療相比，在急性發作期間，每個領域都需要不同的啟動、調整和監測策略。給藥方式引入了一條正交的分化軸：靜脈注射在急性住院治療中占主導地位，而口服方案是慢性門診病人治療的基礎，從而實現了診所和居家照護環境中的連續性。

將終端使用者細分為診所、家庭護理機構和醫院，可以反映治療啟動和維持地點的實際情況，從而影響患者援助計劃、依從性干預措施和監測基礎設施。分銷管道的細微差別——線下與線上，以及醫院與零售藥局之間的線下——會影響治療時間、庫存管理和患者便利性。將這些相互交叉的細分維度結合起來，可以提供多維視角，支持有針對性的臨床通訊協定、差異化的商業策略以及在物流和患者支持方面的商業投資。

區域動態和醫療保健系統特徵決定了全球市場在治療方法採用、報銷途徑和護理服務方面的差異

區域動態對全球心臟衰竭領域的治療方法採用、報銷和交付方式有重大影響。在美洲，付款人結構、整合的交付網路以及專科中心的集中度決定了方案的快速採用，為專科醫生的分佈和醫院主導的治療啟動創造了途徑。私人和公共付款人模式的廣度也影響報銷談判和處方集的佈局，從而影響治療價值的體現。

在歐洲、中東和非洲，法律規範、資金籌措機制和臨床基礎設施的差異導致了醫療服務取得模式的不平衡。國家衛生系統和區域採購機構通常優先考慮成本效益和治療結果，並強調真實世界證據的產生和基於結果的合約簽訂。診斷能力和專科護理可近性的差異可能會改變診所治療啟動和醫院管理之間的平衡。

亞太地區既有擁有先進三級醫療服務的大城市，也有受物流和基礎設施限制的廣大地區。這種多樣性影響了口服慢性病治療方案的採用以及對急性住院治療的依賴，從而提升了數位醫療和遠端醫療在填補醫療缺口方面的作用。在每個地區，當地監管的細微差別、供應鏈的穩健性以及支付方的期望都將決定治療創新如何轉化為可衡量的臨床影響。

整合科學差異化、證據生成和商業夥伴關係以支持治療方法採用的策略性企業優先事項和營運手冊

公司策略日益取決於其如何有效地將科學差異化與整體醫療保健執行相結合。領先的研發和商業機構正將其研發、證據生成和生命週期管理重點放在化合物和組合上，以滿足射血分數保留和降低患者群體中尚未滿足的需求。策略重點包括證明臨床效用、闡明在併發症族群中的安全性，以及產生可操作的證據以支持其在常規實踐中的應用。

在商業性方面，各公司正在最佳化產品上市順序和通路夥伴關係，以管理住院和門診病人維護之間的過渡。與醫院系統、專科藥房和居家照護機構的合作有助於確保啟動途徑的暢通，確保出院後過渡期的連續性，並支持依從性計劃。對真實世界證據平台和病患監測技術的投資，增強了與付款人和整合交付網路進行談判的價值提案。

在營運方面，企業正在完善其供應鏈策略，以降低關稅和採購風險，增強與臨床使用模式相關的預測模型，並制定適合不同區域報銷環境的定價方法。與數位醫療服務提供者和診斷公司的夥伴關係日益普遍，將治療性介入與監測和依從性解決方案相結合，以改善療效並支持長期產品差異化。

為開發商、付款人和供應商提供切實可行的優先行動，以加強臨床和商業途徑的可及性、證據完整性和供應彈性

產業領導者可以採取具體措施，提升心臟衰竭治療的可近性、臨床療效和商業性韌性。首先，將臨床開發和核准後證據項目與對支付方和醫療保健系統至關重要的可操作終點（例如避免住院和功能狀態）相結合，同時開展試驗，確保其能夠捕捉射血分數保留和降低的患者群體相關的異質性患者表現型。其次，設計銜接住院和門診病人的上市和商業化計劃，並與醫院藥房團隊、診所網路和居家照護提供者協調，制定清晰的啟動和交接通訊協定。

此外，優先考慮採購彈性，並透過多元化供應商網路和探索關鍵投入的近岸外包方案來降低關稅波動的風險。投資支持藥物依從性和早期發現脫抑制的數位化和遠端監控工具，提高臨床價值並降低下游成本。積極與付款人合作，制定基於結果的合約機制，使報銷與實際治療結果保持一致。

最後，我們透過將證據產生和定價方法與當地監管和報銷環境結合，強化區域策略。我們組成跨職能團隊，整合臨床、監管、報銷和供應鏈專業知識，執行複雜的上市和生命週期舉措。這些行動幫助領導者將治療前景轉化為持續的臨床和商業性影響，同時確保患者在不同醫療環境中都能獲得治療。

強大的混合方法研究設計結合了領先臨床醫生的意見、主題文獻的綜合和情境分析，確保了可操作和可辯護的見解

本研究採用混合方法，旨在產生嚴謹可行的洞見，將臨床細節與商業性現實連結起來。主要的定性輸入包括對醫院系統、診所和居家照護機構的循環系統、心臟衰竭護士、藥屋主任和採購負責人進行結構化訪談，收集關於治療方法選擇、啟動途徑和依從性挑戰的第一手觀點。這些一線洞見與二次研究相輔相成，二次研究使用同行評審的臨床文獻、監管指南和公開的組織報告來解釋臨床有效性、安全性和指南的演變。

分析方法包括跨治療層級和護理路徑整合、針對射血分數保留和降低人群的表現型特異性臨床映射，以及情境分析，以評估營運對供應鏈變數（例如關稅變化）的反應。透過案例研究研究和供應鏈映射練習，評估劑型和分銷管道的動態，揭示醫院藥房、零售藥房和線上履約管道中的限制和推動因素。區域分析整合了美洲、歐洲、中東和非洲以及亞太地區的監管和報銷考量，揭示了實施的實際意義。

研究結果將跨資訊來源進行三角檢驗，以確保內部一致性和實際相關性。當已發表數據稀缺或快速發展的臨床證據可能改變治療定位時，我們會承認其局限性，並強調可隨著新的臨床和操作數據的出現而更新的適應性策略。

綜合臨床、營運和社區主題，強調將治療方法進展轉化為持續患者利益的實用途徑

摘要，心臟衰竭治療市場格局的特徵是臨床進展顯著且摘要複雜。如今，治療方法差異已超越傳統的血流動力學標靶藥物，涵蓋改善腎臟和代謝功能的藥物，因此需要更細緻的臨床決策路徑，將表現型、嚴重程度和合併症納入考量。這些科學進步與不斷變化的醫療服務模式交織在一起，診所、醫院和居家醫療在啟動、調整和長期管理方面各自發揮不同的作用。

同時，線下醫院和零售藥局的履約，正在塑造分銷和採購格局，需要製定協調一致的策略來維護藥品的可及性並確保醫療服務的連續性。關稅和供應鏈壓力凸顯了多元化採購以及臨床、採購和報銷相關人員之間更緊密合作的必要性。美洲、歐洲、中東和非洲以及亞太地區的區域差異進一步凸顯了針對每個地區制定客製化證據和定價策略的重要性。

最終，如果相關人員將臨床差異化與嚴謹的營運（例如證據生成、供應彈性和付款人參與）結合，將最有能力將治療進展轉化為患者療效的可衡量改善。有針對性的證據投資、跨醫療機構的夥伴關係以及積極主動的供應鏈管理，將把潛力轉化為持續的臨床效益。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • SGLT2抑制劑的採用對心臟衰竭住院率和付款人策略的影響
  • 透過遠端監控和遠端醫療平台整合減少心臟衰竭管理中的再入院率
  • 改善HFrEF患者收縮功能的心肌肌凝蛋白活化劑開發平臺
  • 新型肽基腦啡肽酶抑制劑在治療鬱血性心臟衰竭的市場進入挑戰
  • 生物標記和個人化醫療在指導最佳心臟衰竭治療中的新興作用
  • 生物技術公司與數位醫療公司建立策略合作夥伴關係，用於心臟衰竭患者的遠端管理
  • 不斷變化的監管格局和創新心臟衰竭藥物及診斷的快速核准
  • 以價值為基礎的照護模式對心臟衰竭藥物處方模式的經濟影響

第6章：美國關稅的累積影響（2025年）

第7章：人工智慧（AI）的累積影響（2025年）

第 8 章心臟衰竭藥物市場（依藥物類別）

  • 血管緊張素轉換酶抑制劑
  • ARB
  • BETA受體阻斷劑
  • 利尿劑
  • MRA
  • SGLT2抑制劑

第9章心臟衰竭藥物市場（按心臟衰竭類型）

  • 射血分數保留
    • 急性
    • 慢性的
  • 射血分數降低型
    • 急性
    • 慢性的

第 10 章心臟衰竭藥物市場依給藥方式

  • 靜脈
  • 口服

第 11 章心臟衰竭藥物市場（依最終用戶）

  • 診所
  • 居家醫療
  • 醫院

第 12 章心臟衰竭藥物市場（依分銷管道）

  • 離線
    • 醫院藥房
    • 零售藥局
  • 線上

第13章心臟衰竭藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章心臟衰竭藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國心臟衰竭藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Novartis International AG
    • AstraZeneca PLC
    • Boehringer Ingelheim International GmbH
    • Pfizer Inc.
    • Eli Lilly and Company
    • Bayer AG
    • Laboratoires Servier
    • Boston Scientific Corporation
    • Amgen Inc.
    • Cardurion Pharmaceuticals
Product Code: MRR-430D42AA0D2E

The Heart Failure Therapeutics Market is projected to grow by USD 60.23 billion at a CAGR of 10.98% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 26.16 billion
Estimated Year [2025] USD 29.10 billion
Forecast Year [2032] USD 60.23 billion
CAGR (%) 10.98%

Concise contextual framing of contemporary heart failure therapeutics highlighting clinical priorities, care pathways, and operational decision levers for stakeholders

Heart failure therapeutics occupy a pivotal intersection of clinical urgency, evolving molecular science, and shifting care delivery models. This executive summary synthesizes the contemporary landscape for clinicians, payers, industry leaders, and policy makers, emphasizing the therapeutic classes and care pathways that matter most in shaping patient outcomes. The introduction situates recent therapeutic advances against a backdrop of changing clinical guidelines and heightened attention to chronic disease management, framing the rest of the analysis around practical implications rather than abstract projections.

The discussion foregrounds how incremental innovations across established drug classes, alongside newer agents and adjunctive care strategies, are redefining treatment algorithms. It emphasizes the practical considerations that influence adoption in routine care, such as route of administration, acute versus chronic management distinctions, and where care is delivered-clinic, hospital, or home settings. By anchoring the narrative to real-world decision levers, this section prepares the reader for deeper analysis of landscape shifts, tariff impacts, segmentation insights, and regional dynamics that follow.

Throughout, the tone balances clinical nuance and commercial pragmatism. The introduction does not seek to catalog every development but rather to clarify the themes that determine therapeutic value, stakeholder priorities, and the operational adjustments organizations will need to make to capitalize on emerging opportunities in heart failure care.

Detailed analysis of how pharmacologic innovation, refined phenotyping, and evolving care delivery models are jointly reshaping therapeutic strategies and access pathways

The therapeutic landscape for heart failure is undergoing transformative shifts driven by a confluence of innovation, guideline evolution, and care delivery redesign. Advances in pharmacology are broadening the clinician's toolkit beyond traditional modulators of hemodynamics to include agents that target metabolic, inflammatory, and renal-cardiac axes. As a result, established categories such as ACE inhibitors, ARBs, beta blockers, diuretics, MRAs, and SGLT2 inhibitors are being re-evaluated within more finely stratified treatment pathways, while combination strategies and sequencing considerations gain prominence.

Concurrently, diagnostic refinements and a deeper understanding of phenotype heterogeneity have sharpened focus on preserved versus reduced ejection fraction subtypes, and on acute as distinct from chronic management. These clinical delineations affect therapeutic selection, monitoring intensity, and expected outcomes. Mode-of-administration preferences are also shifting, as oral chronic regimens interact with intermittent or acute intravenous interventions tied to hospitalization patterns and home-based care expansion.

Operationally, distribution and access channels show parallel transformation. Offline channels anchored in hospital and retail pharmacies remain essential for acute care and specialty dispensing, while online fulfillment and telehealth-enabled prescribing are gaining traction for chronic medication continuity. End-user dynamics-clinics, home care settings, and hospitals-are adapting to new protocols for initiation, titration, and monitoring, reshaping how evidence translates into practice. The cumulative effect is a landscape where therapeutic choice, care setting, and access mechanisms co-evolve rapidly, demanding coordinated strategies across clinical, commercial, and policy domains.

Comprehensive appraisal of recent tariff-driven supply chain effects and their operational consequences for procurement, distribution, and therapeutic access frameworks

Recent tariff developments in the United States have introduced layered implications for manufacturers, distributors, and downstream care providers operating in the heart failure therapeutics space. Tariff changes influence cost structures across the supply chain, affecting the landed cost of active pharmaceutical ingredients, finished dose formulations, and device-adjacent products used in monitoring and administration. These pressures can alter contracting dynamics with hospital systems and pharmacy networks and may prompt re-evaluation of procurement strategies for both public and private payers.

The operational ripple effects extend to channel economics. Hospital pharmacy procurement practices, retail pharmacy stocking decisions, and online distribution agreements are sensitive to input-cost variability created by tariff adjustments. In response, manufacturers may pursue localized sourcing, alternative supplier partnerships, or renegotiated distribution terms to preserve margin and ensure uninterrupted patient access. Similarly, providers under value-based payment arrangements might reassess formularies and therapeutic pathways to manage total cost of care while maintaining clinical standards.

Clinicians and health system leaders will need to balance short-term operational adjustments with long-term resilience measures. This entails closer coordination among supply chain, pharmacy, and clinical leadership, increased scenario planning for potential supply disruptions, and strategic dialogue with payers to preserve access to guideline-recommended therapies. Ultimately, tariff-induced cost pressures act as a catalyst for more integrated procurement and therapeutic stewardship practices across the delivery ecosystem.

Multidimensional segmentation insights that reconcile drug class, phenotype distinctions, administration routes, care settings, and distribution architectures to inform targeted strategies

Segmentation provides the analytical scaffolding needed to translate therapeutic nuance into actionable strategy. When viewed through the lens of drug class differentiation, therapeutic choice varies markedly: ACE inhibitors and ARBs remain foundational for neurohormonal modulation, beta blockers address sympathetic overactivity, diuretics manage fluid balance in symptomatic patients, MRAs contribute to mineralocorticoid antagonism, and SGLT2 inhibitors offer metabolic and renal-cardiac benefits that cross traditional class boundaries. These class-level distinctions directly shape clinical pathways and commercial positioning.

Disaggregating by heart failure type further refines decision-making. Preserved ejection fraction and reduced ejection fraction represent biologically and operationally distinct domains; within each, acute episodes necessitate different initiation, titration, and monitoring strategies compared with chronic maintenance care. Mode of administration introduces an orthogonal axis of differentiation: intravenous therapy dominates the acute, inpatient context, while oral regimens support chronic outpatient management and enable continuity across clinic and home care settings.

End-user segmentation-clinics, home care settings, and hospitals-captures the practical realities of where therapies are initiated and maintained, influencing patient support programs, adherence interventions, and monitoring infrastructure. Distribution channel nuances between offline and online channels, with offline further split into hospital and retail pharmacies, affect time-to-treatment, inventory management, and patient convenience. Together, these intersecting segmentation axes provide a multidimensional view that supports targeted clinical protocols, differentiated commercial strategies, and operational investments in logistics and patient support.

Regional dynamics and health system characteristics that shape therapeutic adoption, reimbursement pathways, and care delivery variations across global markets

Regional dynamics exert a powerful influence on how therapies are adopted, reimbursed, and delivered across the global heart failure landscape. In the Americas, payer structures, integrated delivery networks, and a high concentration of specialist centers shape rapid protocol adoption and create pathways for specialty distribution and hospital-led therapeutics initiation. The breadth of private and public payer models also affects reimbursement negotiations and formulary placements, with implications for how therapeutic value is demonstrated.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks, funding mechanisms, and clinical infrastructure leads to variable uptake patterns. National health systems and regional procurement bodies often prioritize cost-effectiveness and therapeutic outcomes, which drives emphasis on real-world evidence generation and outcomes-based contracting. Differences in diagnostic capacity and access to specialty care can alter the balance between clinic-based initiation and hospital-centered management.

Asia-Pacific presents both large urban centers with advanced tertiary care and vast regions where access is constrained by logistics and infrastructure. This diversity influences the adoption of oral chronic regimens versus reliance on acute inpatient interventions, and it elevates the role of digital health and telemedicine in bridging care gaps. Across all regions, local regulatory nuance, supply-chain robustness, and payer expectations will determine how therapeutic innovations translate into measurable clinical impact.

Strategic corporate priorities and operational playbooks that integrate scientific differentiation, evidence generation, and distribution partnerships to support therapeutic adoption

Company strategies are increasingly defined by how effectively they align scientific differentiation with operational execution across the care continuum. Leading developers and commercial organizations are concentrating R&D, evidence generation, and lifecycle management around compounds and combinations that address unmet needs within preserved and reduced ejection fraction populations. Strategic priorities include demonstrating benefit in hard clinical outcomes, elucidating safety profiles across comorbid populations, and generating pragmatic evidence that supports adoption in routine practice.

On the commercial front, firms are optimizing launch sequencing and channel partnerships to manage the transition between inpatient initiation and outpatient maintenance. Collaboration with hospital systems, specialty pharmacies, and home care providers helps secure pathways for initiation, ensures continuity during post-discharge transitions, and supports adherence programs. Investments in real-world evidence platforms and patient monitoring technologies strengthen value propositions in negotiations with payers and integrated delivery networks.

Operationally, companies are also refining supply chain strategies to mitigate tariff and sourcing risks, enhancing forecasting models tied to clinical utilization patterns, and developing tailored pricing approaches for diverse regional reimbursement landscapes. Partnerships with digital health providers and diagnostics companies are increasingly common, aimed at connecting therapeutic interventions with monitoring and adherence solutions that improve outcomes and support long-term product differentiation.

Practical, prioritized actions for developers, payers, and providers to enhance access, evidence alignment, and supply resilience across clinical and commercial pathways

Industry leaders can take concrete steps to strengthen therapeutic access, clinical outcomes, and commercial resilience in heart failure care. First, align clinical development and post-approval evidence programs with the practical endpoints that matter to payers and health systems, such as hospitalization avoidance and functional status, while ensuring trials capture heterogeneous patient phenotypes relevant to preserved and reduced ejection fraction populations. Second, design launch and commercialization plans that bridge inpatient and outpatient settings, coordinating with hospital pharmacy teams, clinic networks, and home care providers to create clear initiation and handoff protocols.

Additionally, prioritize procurement resilience by diversifying supplier networks and exploring near-shoring options for critical inputs to reduce exposure to tariff volatility. Invest in digital and remote-monitoring tools that support adherence and early detection of decompensation, thereby enhancing clinical value and reducing downstream costs. Engage proactively with payers to develop outcome-based contracting mechanisms that align reimbursement with real-world therapeutic performance.

Finally, strengthen regional strategies by tailoring evidence generation and pricing approaches to local regulatory and reimbursement contexts. Build cross-functional teams that integrate clinical, regulatory, reimbursement, and supply chain expertise to execute complex market entry and lifecycle initiatives. These actions will help leaders convert therapeutic promise into sustained clinical and commercial impact while preserving access for patients across diverse care settings.

Robust mixed-methods research design combining frontline clinician input, targeted literature synthesis, and scenario analysis to ensure actionable and defensible insights

This research employs a mixed-methods approach designed to produce rigorous, actionable insights that bridge clinical nuance and commercial realities. Primary qualitative inputs include structured interviews with practicing cardiologists, heart failure nurses, pharmacy directors, and procurement leaders across hospital systems, clinics, and home care providers to capture firsthand perspectives on therapeutic choice, initiation pathways, and adherence challenges. These frontline insights are complemented by secondary research drawing on peer-reviewed clinical literature, regulatory guidance, and publicly available health system reports to contextualize clinical efficacy, safety, and guideline evolution.

Analytical methods include cross-sectional synthesis of therapeutic classes and care pathways, phenotype-specific clinical mapping for preserved and reduced ejection fraction populations, and scenario analysis to evaluate operational responses to supply-chain variables such as tariff changes. Mode-of-administration and distribution channel dynamics are assessed through case studies and supply-chain mapping exercises that highlight constraints and enablers across hospital pharmacies, retail pharmacies, and online fulfillment channels. Regional analysis integrates regulatory and reimbursement considerations across the Americas, Europe, Middle East & Africa, and Asia-Pacific to identify practical implications for adoption.

Throughout, findings have been triangulated across sources to ensure internal consistency and practical relevance. Limitations are acknowledged where public data are sparse or where rapidly evolving clinical evidence may alter therapeutic positioning, and recommendations emphasize adaptable strategies that can be updated as new clinical and operational data emerge.

Consolidated synthesis of clinical, operational, and regional themes underscoring pragmatic pathways to convert therapeutic advances into sustained patient benefit

In summary, the heart failure therapeutics landscape is characterized by substantive clinical evolution and operational complexity. Therapeutic differentiation now extends beyond traditional hemodynamic targets to include agents that deliver renal and metabolic benefits, necessitating more nuanced clinical decision pathways that account for phenotype, acuity, and comorbidity. These scientific advances intersect with shifting care delivery models, where clinics, hospitals, and home care settings each play distinct roles in initiation, titration, and long-term management.

At the same time, distribution and procurement dynamics-shaped by offline hospital and retail pharmacy practices as well as growing online fulfillment-require coordinated strategies to maintain access and ensure continuity of care. Tariff and supply-chain pressures underscore the need for diversified sourcing and tighter alignment between clinical, procurement, and reimbursement stakeholders. Regional variation across the Americas, Europe, Middle East & Africa, and Asia-Pacific further highlights the importance of locally tailored evidence and pricing strategies.

Ultimately, stakeholders who integrate clinical differentiation with operational rigor-aligning evidence generation, supply resilience, and payer engagement-will be best positioned to translate therapeutic advances into measurable improvements in patient outcomes. The path forward emphasizes pragmatism: targeted investments in evidence, partnerships across care settings, and proactive supply-chain management will convert potential into sustained clinical benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Impact of SGLT2 inhibitor adoption on heart failure hospitalization rates and payer strategies
  • 5.2. Integration of remote monitoring and telehealth platforms in heart failure management to reduce readmissions
  • 5.3. Development pipeline advancements in cardiac myosin activators for improved systolic function in HFrEF patients
  • 5.4. Market access challenges for novel peptide-based neprilysin inhibitors in congestive heart failure therapy
  • 5.5. Emerging role of biomarkers and personalized medicine in guiding heart failure treatment optimization
  • 5.6. Strategic partnerships between biotech and digital health companies for heart failure remote patient management
  • 5.7. Regulatory landscape evolution and expedited approvals for innovative heart failure therapeutics and diagnostics
  • 5.8. Economic implications of value-based care models on prescription patterns of heart failure drugs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Heart Failure Therapeutics Market, by Drug Class

  • 8.1. Ace Inhibitors
  • 8.2. Arbs
  • 8.3. Beta Blockers
  • 8.4. Diuretics
  • 8.5. Mras
  • 8.6. SGLT2 Inhibitors

9. Heart Failure Therapeutics Market, by Heart Failure Type

  • 9.1. Preserved Ejection Fraction
    • 9.1.1. Acute
    • 9.1.2. Chronic
  • 9.2. Reduced Ejection Fraction
    • 9.2.1. Acute
    • 9.2.2. Chronic

10. Heart Failure Therapeutics Market, by Mode Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Heart Failure Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care Settings
  • 11.3. Hospitals

12. Heart Failure Therapeutics Market, by Distribution Channel

  • 12.1. Offline
    • 12.1.1. Hospital Pharmacies
    • 12.1.2. Retail Pharmacies
  • 12.2. Online

13. Heart Failure Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Heart Failure Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Heart Failure Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis International AG
    • 16.3.2. AstraZeneca PLC
    • 16.3.3. Boehringer Ingelheim International GmbH
    • 16.3.4. Pfizer Inc.
    • 16.3.5. Eli Lilly and Company
    • 16.3.6. Bayer AG
    • 16.3.7. Laboratoires Servier
    • 16.3.8. Boston Scientific Corporation
    • 16.3.9. Amgen Inc.
    • 16.3.10. Cardurion Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. HEART FAILURE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. HEART FAILURE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HEART FAILURE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN HEART FAILURE THERAPEU